Table Graph
   

favipiravir - versus potential COVID-19 treatments - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 0.98 [0.02, 50.37]< 10%1 study (1/-)50.4 %NAnot evaluable crucial-
deaths 1.12 [0.02, 62.74]< 10%1 study (1/-)47.9 %NAnot evaluable crucial-
clinical improvement 1.25 [0.21, 7.62]> 10%1 study (1/-)59.5 %NAnot evaluable important-
clinical improvement (14-day) 1.25 [0.21, 7.62]> 10%1 study (1/-)59.5 %NAnot evaluable important-
death or ventilation 3.60 [0.13, 102.66]< 10%1 study (1/-)23.0 %NAnot evaluable important-
radiologic improvement (14-day) 1.50 [0.08, 28.48]> 187%2 studies (2/-)60.4 %lownot evaluable highimportant-
viral clearance 0.67 [0.37, 1.24]> 10%2 studies (2/-)10.1 %highnot evaluable lowimportant-
viral clearance (time to event analysis only) 0.71 [0.38, 1.31]> 10%1 study (1/-)13.5 %NAnot evaluable important-
viral clearance by day 14 0.18 [0.01, 4.75]> 10%1 study (1/-)15.7 %NAnot evaluable important-
ICU admission 5.43 [0.21, 139.89]< 10%1 study (1/-)15.7 %NAnot evaluable non important-

safety endpoints 00

adverse events 0.18 [0.04, 0.89]< 138%2 studies (2/-)98.2 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons